company background image
ISOF

Isofol Medical OM:ISOFOL Stock Report

Last Price

kr1.28

Market Cap

kr206.1m

7D

0.5%

1Y

-85.3%

Updated

18 Aug, 2022

Data

Company Financials +
ISOFOL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ISOFOL Stock Overview

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally.

Isofol Medical AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Isofol Medical
Historical stock prices
Current Share Pricekr1.28
52 Week Highkr14.44
52 Week Lowkr1.08
Beta1.42
1 Month Change-83.85%
3 Month Change-86.21%
1 Year Change-85.32%
3 Year Change-94.73%
5 Year Change-94.17%
Change since IPO-95.27%

Recent News & Updates

Shareholder Returns

ISOFOLSE BiotechsSE Market
7D0.5%-0.3%0.05%
1Y-85.3%-19.6%-19.8%

Return vs Industry: ISOFOL underperformed the Swedish Biotechs industry which returned -21.2% over the past year.

Return vs Market: ISOFOL underperformed the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is ISOFOL's price volatile compared to industry and market?
ISOFOL volatility
ISOFOL Average Weekly Movement25.3%
Biotechs Industry Average Movement8.7%
Market Average Movement7.1%
10% most volatile stocks in SE Market12.3%
10% least volatile stocks in SE Market4.5%

Stable Share Price: ISOFOL is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: ISOFOL's weekly volatility has increased from 15% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200815Jarl Jungneliushttps://isofolmedical.com

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital.

Isofol Medical AB (publ) Fundamentals Summary

How do Isofol Medical's earnings and revenue compare to its market cap?
ISOFOL fundamental statistics
Market Capkr206.09m
Earnings (TTM)-kr200.25m
Revenue (TTM)kr22.41m

9.2x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISOFOL income statement (TTM)
Revenuekr22.41m
Cost of Revenuekr196.71m
Gross Profit-kr174.30m
Other Expenseskr25.95m
Earnings-kr200.25m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 23, 2022

Earnings per share (EPS)-1.24
Gross Margin-777.90%
Net Profit Margin-893.70%
Debt/Equity Ratio0%

How did ISOFOL perform over the long term?

See historical performance and comparison